Mantroxate 250 mg (Abiraterone Acetate): Complete Clinical Guide to Dosing, Mechanism, Safety & Therapeutic Alternatives in Advanced Prostate Cancer

[Insert Mantroxate 250 mg Product Image Here]

1. What is Mantroxate (Abiraterone Acetate 250 mg)?

Mantroxate is a branded generic formulation of abiraterone acetate, a first-in-class steroidal androgen biosynthesis inhibitor that has fundamentally reshaped the therapeutic landscape for men with advanced prostate cancer. Unlike traditional androgen deprivation therapy (ADT), which suppresses testicular testosterone production through surgical orchiectomy or gonadotropin-releasing hormone (GnRH) analogues, abiraterone acetate operates at a deeper biochemical level by shutting down androgen synthesis at all three anatomical sources simultaneously: the gonads, the adrenal cortex, and the prostate tumour tissue itself.

The active compound is administered as a prodrug — abiraterone acetate — which undergoes rapid hydrolysis in the liver and peripheral tissues to yield the pharmacologically active metabolite, abiraterone. This active moiety then exerts its antineoplastic effect by irreversibly inhibiting the cytochrome P450 17A1 (CYP17) enzyme complex, a critical catalyst in the steroidogenic pathway that converts pregnenolone and progesterone into androgen precursors such as dehydroepiandrosterone (DHEA) and androstenedione.

Mantroxate is manufactured by Hikma Specialized Pharmaceuticals, a globally recognised generic and branded-generic pharmaceutical company headquartered in Jordan with manufacturing facilities compliant with US FDA and European EMA standards. The product is registered across multiple Middle Eastern and North African markets and represents a cost-effective bioequivalent alternative to the originator brand Zytiga (Janssen). For a broader overview of oncology therapeutics, consult the Pharma Guide Comprehensive Drug Index.

2. Detailed Composition & Mechanism of Action

Each film-coated tablet of Mantroxate contains 250 mg of abiraterone acetate alongside a carefully selected array of pharmaceutical excipients designed to ensure consistent disintegration, dissolution, and bioavailability within the gastrointestinal tract:

Molecular Pharmacology: Tri-Source Androgen Suppression

The therapeutic brilliance of abiraterone lies in its capacity to achieve what conventional ADT alone cannot. Standard GnRH agonists or antagonists effectively silence testicular testosterone production, yet prostate cancer cells adapt by upregulating intratumoural steroidogenic enzymes and exploiting adrenal androgen precursors to sustain growth signalling through the androgen receptor (AR). Abiraterone eliminates this escape route by targeting CYP17, a bifunctional enzyme expressed in all three androgen-producing tissues:

1. 17α-Hydroxylase activity blockade: Prevents the conversion of pregnenolone to 17-hydroxypregnenolone and progesterone to 17-hydroxyprogesterone — the obligatory first step in the androgen and cortisol biosynthetic cascades.
2. C17,20-Lyase activity blockade: Prevents the subsequent cleavage of 17-hydroxypregnenolone and 17-hydroxyprogesterone into DHEA and androstenedione, respectively — the direct precursors of testosterone and dihydrotestosterone (DHT).

The net pharmacodynamic result is a reduction in circulating testosterone to undetectable levels (below the limit of quantification), even in patients whose disease has progressed despite castrate-level suppression via ADT. This profound androgen depletion deprives prostate cancer cells of their principal proliferative signal, triggering apoptotic cell death, tumour regression, and a corresponding decline in serum prostate-specific antigen (PSA).

3. Clinical Indications & Therapeutic Uses

Mantroxate (abiraterone acetate) is indicated in accordance with ASCO, EAU, and NCCN guideline recommendations for the following adult male patient populations:

• Metastatic Castration-Resistant Prostate Cancer (mCRPC): Indicated for men whose disease has progressed radiographically or biochemically (rising PSA) despite castrate serum testosterone levels (<50 ng/dL) achieved through bilateral orchiectomy or continuous GnRH analogue therapy. Abiraterone is approved both in the pre-chemotherapy setting (chemotherapy-naïve mCRPC, based on the COU-AA-302 trial) and in the post-docetaxel setting (COU-AA-301 trial), where it demonstrated statistically significant improvements in overall survival, radiographic progression-free survival, and PSA response rates compared to placebo plus prednisone.
• High-Risk Metastatic Castration-Sensitive Prostate Cancer (mCSPC / mHSPC): Indicated in combination with ADT and prednisone for men newly diagnosed with metastatic hormone-sensitive disease exhibiting high-risk features. The landmark LATITUDE trial established that upfront abiraterone plus prednisone and ADT reduced the risk of death by 38% compared to ADT alone, while significantly delaying the onset of skeletal-related events, pain progression, and the need for subsequent cytotoxic chemotherapy.

4. Dosage Regimens & Administration Guidelines

Standard Adult Dosing Protocol

• Mantroxate (abiraterone acetate): The recommended dose is 1,000 mg taken orally once daily, achieved by swallowing four 250 mg tablets together at the same time each day with a full glass of water. Tablets must be swallowed whole — they must not be crushed, chewed, or split.
• Concomitant Prednisone / Prednisolone:
  • For mCRPC: Prednisone 5 mg orally twice daily (total 10 mg/day).
  • For mCSPC: Prednisone 5 mg orally once daily.
  The corticosteroid co-administration is not optional — it is a pharmacological necessity to prevent secondary mineralocorticoid excess (see mechanism explanation below).
• Continuous ADT: Patients who have not undergone bilateral orchiectomy must continue receiving GnRH agonist or antagonist injections (e.g., goserelin, leuprorelin, degarelix) throughout the entire duration of Mantroxate therapy to maintain castrate testosterone levels.

Critical Administration Rule: Strict Fasting Requirement

This is the single most important adherence instruction for patients taking abiraterone acetate. Mantroxate tablets must be consumed on a completely empty stomach:

• Take the tablets at least 1 hour before eating any food, or at least 2 hours after your last meal.
• During the fasting window, only plain water is permitted. No milk, juice, tea, coffee, or nutritional supplements.
• Pharmacokinetic rationale: Co-ingestion of abiraterone with food — particularly high-fat meals — produces a dramatic, unpredictable increase in systemic drug exposure. Clinical pharmacokinetic studies have demonstrated that a high-fat meal can elevate the area under the curve (AUC) of abiraterone by up to 10- to 17-fold compared to the fasted state. This uncontrolled surge in plasma concentration substantially amplifies the risk of dose-dependent hepatotoxicity, mineralocorticoid excess, and cardiac arrhythmias.

Why is Prednisone Mandatory?

The inhibition of CYP17 by abiraterone does not selectively target androgen synthesis alone — it simultaneously blocks cortisol production in the adrenal zona fasciculata. The resulting hypocortisolaemia triggers a compensatory surge in adrenocorticotropic hormone (ACTH) secretion from the anterior pituitary via loss of negative feedback. Elevated ACTH drives the accumulation of upstream mineralocorticoid precursors (corticosterone and deoxycorticosterone), producing a syndrome of mineralocorticoid excess characterised by hypertension, hypokalaemia, and fluid retention. Low-dose prednisone replaces the suppressed cortisol, restores negative feedback on the hypothalamic-pituitary-adrenal axis, and effectively prevents this dangerous cascade.

Missed Dose & Overdose Management

If a dose of Mantroxate or prednisone is missed, the patient should skip the forgotten dose entirely and resume the regular schedule the following day. Doubling the dose to compensate for a missed tablet is contraindicated. In the event of accidental overdose, immediate medical evaluation is warranted with close monitoring of hepatic transaminases, serum electrolytes (particularly potassium), blood pressure, and cardiac rhythm. No specific antidote exists; management is supportive and symptomatic.

5. Adverse Drug Reactions & Contraindications

Mineralocorticoid Excess Syndrome (Very Common, >10%)

• Hypertension: Reported in 10–20% of patients. Blood pressure should be measured at least weekly during the first month and monthly thereafter. Antihypertensive therapy may need to be initiated or intensified.
• Hypokalaemia: Manifests as muscle weakness, leg cramps, palpitations, and fatigue. Serum potassium must be checked at baseline, biweekly for the first three months, and monthly thereafter. Potassium supplementation may be required.
• Peripheral oedema and fluid retention: Bilateral ankle and lower leg swelling is common and may necessitate diuretic therapy (spironolactone is preferred due to its anti-mineralocorticoid properties, though its use requires oncologist approval given theoretical AR agonism concerns).

Hepatotoxicity (Common, 1–10%)

Abiraterone can cause clinically significant elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin. Hepatic function tests must be performed every two weeks during the first three months of therapy and monthly thereafter. If ALT or AST exceeds 5× the upper limit of normal (ULN) or bilirubin exceeds 3× ULN, treatment should be interrupted until values return to baseline or ≤2× ULN, then restarted at a reduced dose of 500 mg daily with intensified monitoring. Permanent discontinuation is mandated if hepatotoxicity recurs at the reduced dose.

Other Frequently Reported Adverse Events

• Fatigue and asthenia (very common, often multifactorial).
• Hot flushes and night sweats (consequence of profound androgen deprivation).
• Arthralgia, myalgia, and accelerated bone mineral density loss (long-term ADT effect).
• Gastrointestinal disturbances: diarrhoea, dyspepsia, mild nausea.
• Haematological changes: anaemia, lymphopenia, and mild hypertriglyceridaemia.
• Urinary tract infections and upper respiratory tract infections.

Absolute Contraindications

• Severe hepatic impairment (Child-Pugh Class C) — use is strictly prohibited.
• Known hypersensitivity to abiraterone acetate or any tablet excipient.
• Women who are pregnant or may become pregnant (FDA Pregnancy Category X) — including handling of crushed or broken tablets without protective gloves.

6. Drug Interactions & Dietary Precautions

• Strong CYP3A4 Inducers (Avoid): Rifampicin, carbamazepine, phenytoin, phenobarbital, and St. John’s Wort (Hypericum perforatum) dramatically accelerate abiraterone metabolism, potentially reducing plasma concentrations to sub-therapeutic levels and compromising oncological efficacy. Co-administration should be avoided; if unavoidable, the oncologist may consider dose escalation with intensified monitoring.
• Strong CYP3A4 Inhibitors (Use with Caution): Ketoconazole, itraconazole, clarithromycin, and ritonavir can elevate abiraterone plasma levels, increasing the risk of hepatotoxicity and mineralocorticoid excess. Dose adjustments and closer laboratory surveillance are warranted.
• CYP2D6 Substrates (Monitor Closely): Abiraterone is a moderate inhibitor of CYP2D6. Concomitant use with narrow therapeutic index CYP2D6 substrates — such as flecainide, propafenone, metoprolol, and certain tricyclic antidepressants — may elevate their plasma concentrations and increase the risk of toxicity. Therapeutic drug monitoring or dose reduction of the co-administered agent may be necessary.
• QT-Prolonging Medications: Caution is advised when combining abiraterone with agents known to prolong the QTc interval (e.g., amiodarone, sotalol, moxifloxacin), particularly in the setting of concurrent hypokalaemia or hypomagnesaemia.
• Food and Grapefruit: As emphasised above, food intake must be strictly avoided around the time of dosing. Grapefruit and grapefruit juice should be entirely eliminated from the diet, as furanocoumarins in grapefruit inhibit intestinal CYP3A4 and can unpredictably increase abiraterone bioavailability.

7. Special Populations & Clinical Considerations

• Women & Pregnancy (FDA Category X — Absolute Contraindication): Mantroxate is indicated exclusively for male patients. Women of childbearing potential must not handle crushed, broken, or damaged tablets without nitrile or latex gloves, as abiraterone is readily absorbed transdermally and can cause catastrophic foetal harm, including ambiguous genitalia in male foetuses and pregnancy loss. Male patients with partners who are pregnant or capable of becoming pregnant must use a condom with an additional effective contraceptive method throughout treatment and for at least 3 months after the final dose.
• Hepatic Impairment:
  • Child-Pugh A (mild): No initial dose adjustment required; standard monitoring applies.
  • Child-Pugh B (moderate): Reduce starting dose to 250 mg once daily with weekly LFT monitoring.
  • Child-Pugh C (severe): Absolutely contraindicated — the risk of fulminant hepatic failure outweighs any potential benefit.
• Renal Impairment: No dose modification is required for patients with mild-to-moderate renal dysfunction. Abiraterone is primarily metabolised hepatically and excreted via the biliary-faecal route, with negligible renal clearance. However, caution is warranted in patients with renal impairment complicated by hypertension or electrolyte imbalances.
• Cardiovascular Disease: Patients with pre-existing heart failure, uncontrolled hypertension, or significant arrhythmias should have these conditions optimally managed before initiating Mantroxate. Baseline and periodic echocardiography may be indicated in high-risk individuals.
• Bone Health: Prolonged androgen deprivation combined with chronic low-dose corticosteroid use accelerates bone mineral density loss. Baseline DEXA scanning, calcium and vitamin D supplementation, and consideration of bone-modifying agents (zoledronic acid or denosumab) are recommended for all patients on long-term therapy. For further reading on specialised care considerations, visit the Women’s Specialised Clinical Care section (relevant for female caregivers and partners).

8. Generic Equivalents & Therapeutic Alternatives

The advanced prostate cancer treatment landscape offers several next-generation hormonal agents alongside abiraterone. The following comparison highlights the principal therapeutic options available to oncologists:

The selection between these agents depends on disease stage, prior treatment exposure, comorbidity profile (particularly cardiovascular and seizure risk), patient preference regarding dosing convenience, and regional formulary availability. Dr. Ahmad Baker and the Pharma Guide clinical team can assist patients and caregivers in understanding these complex therapeutic decisions.

9. Regional Availability & Authentication Guide

• Regulatory Pricing (Egypt): The officially registered price for Mantroxate 250 mg (120 tablets, Hikma) is approximately 26,600 EGP per pack, representing a full 30-day treatment course at the standard 1,000 mg daily dose. This pricing reflects the Egyptian Drug Authority’s mandatory pricing framework and is significantly lower than the originator Zytiga, improving patient access to life-prolonging therapy.
• Insurance & Government Coverage: Abiraterone acetate is included in the approved treatment protocols of Egypt’s Universal Health Insurance system and the state-funded Medical Councils’ oncology committees. Eligible patients can obtain fully subsidised treatment through national cancer centres and specialised medical council decisions following multidisciplinary tumour board review and documentation of clinical eligibility criteria.
• Procurement & Authenticity Verification: Mantroxate is available through hospital oncology pharmacies, major retail pharmacy chains specialising in cancer medications, and authorised distribution networks. Always verify the Hikma holographic seal, batch/lot number, expiry date, and GTIN barcode on the outer carton. Report any packaging irregularities to the manufacturer’s pharmacovigilance department and the national drug regulatory authority.
• Storage Conditions: Store at room temperature below 30°C in a dry location protected from direct sunlight and moisture. Keep the tablets in their original blister packaging until the moment of administration. Store securely out of reach of children and, critically, away from any contact with pregnant women.

10. Clinical Pharmacist Verdict & Bottom Line

Key Clinical Advantages ✅

• Proven survival benefit: Landmark phase III trials (COU-AA-301, COU-AA-302, LATITUDE) have conclusively demonstrated statistically significant overall survival improvements in both mCRPC and mCSPC settings.
• Oral home-based therapy: Eliminates the need for frequent hospital infusion visits required by IV chemotherapy, preserving quality of life and reducing healthcare system burden.
• Cost-effective bioequivalent: As a Hikma-manufactured generic, Mantroxate offers equivalent pharmacokinetic and pharmacodynamic profiles to the originator Zytiga at a substantially lower price point, broadening access across resource-constrained healthcare systems.
• Effective skeletal protection: Significant delays in time to skeletal-related events and pain progression, reducing the devastating impact of bone metastases.

Notable Limitations ❌

• Rigid fasting requirement: The strict empty-stomach administration rule demands considerable lifestyle discipline and can be challenging for patients with irregular eating patterns or gastrointestinal comorbidities.
• Mandatory corticosteroid co-therapy: Chronic prednisone use carries its own metabolic risks including hyperglycaemia, osteoporosis, immunosuppression, and mood disturbances.
• Intensive monitoring burden: Biweekly liver function tests, regular electrolyte panels, and blood pressure surveillance impose a significant logistical commitment on patients and caregivers, particularly during the first three months.

Bottom Line: Mantroxate (abiraterone acetate) 250 mg represents a cornerstone of modern hormonal therapy for advanced prostate cancer, offering robust survival gains and meaningful quality-of-life improvements when administered correctly. Its clinical value is maximised when patients adhere strictly to the fasting protocol, maintain uninterrupted prednisone co-administration, and comply with the rigorous laboratory monitoring schedule. All treatment decisions must be made in close collaboration with the supervising medical oncologist.

❓ Frequently Asked Clinical Questions